tailieunhanh - Báo cáo y học: "XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer. | Int. J. Med. Sci. 2008 5 341 International Journal of Medical Sciences ISSN 1449-1907 2008 5 6 341-346 Ivyspring International Publisher. All rights reserved Short Research Communication XeNA Capecitabine Plus Docetaxel With or Without Trastuzumab as Preoperative Therapy for Early Breast Cancer Stefan Gluck1 H Edward F. McKenna Jr2 Melanie Royce3 1. Miller School of Medicine University of Miami Miami FL 33136 USA 2. Medical Affairs Oncology Roche Nutley NJ 07110-1199 USA 3. University of New Mexico Cancer Research and Treatment Center Albuquerque NM 87131 USA H Correspondence to Stefan Gluck MD PhD Professor of Medicine Associate Division Chief Clinical Affairs Division of Hematol-ogy Oncology Clinical Director Braman Family Breast Cancer Institute UMSylvester Comprehensive Cancer Center University of Miami Miller School of Medicine 1475 NW 12th Ave. Suite 3510 Miami FL 33136. Tel 305-243-4909 Fax 305-243-4047 E-mail SGluck@. Received Accepted Published Combinations of capecitabine and a taxane are highly active in metastatic breast cancer and synergy between capecitabine and docetaxel has also been demonstrated. Such combinations potentially would provide a promising non-anthracycline-based alternative for patients with early breast cancer. Non-anthracycline preoperative regimens are a particularly interesting proposition in human epidermal growth factor receptor 2 HER2 -positive breast cancer as they offer less cardiotoxicity and thus can be used concomitantly with preoperative trastuzumab therapy. Capecitabine plus docetaxel XT and trastuzumab with XT HXT are promising non-anthracycline regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer respectively. The Xeloda in Neoadjuvant XeNA trial an open-label multicenter phase II study independently assesses the efficacy of preoperative XT in HER2-negative and HXT in HER2-positive breast cancer. A particularly .